Contract Research & Services
Contract Research

Cannabis Science to start in-house clinical research with IGXBio's immunotherapy

Published 04 November 2016

Cannabis Science said its in-house lab is almost complete and has started clinical development plans to start working with its partner IGXBio to develop effective cannabinoid therapeutics using IGXBio's Immunotherapy (GenePro, also referred to as Δ4SHIVKU2) FDA Investigational New Drug (IND) Number 015982.

Again, we are looking to further cement our foothold in the substantial pharmaceutical drug development industry, we expect our IGXBio, GenePro drug development program to be a major pharmaceutical success.

Cannabis Science chief medical officer Allen Herman said: Coupled with our property development deals we are securing the required land base to supply a major nationwide pharmaceutical demand. Our program specifics are underway and we will update progress and results as they come in."

About GenePro

GenePro is an investigational DNA immunotherapy sponsored by IGXBio and would be considered a biologic. The Cannabis Science partnership is working to identify and develop agonist cannabinoids and IGXBio's GenePro.

GenePro is a deoxyribonucleic acid (DNA) plasmid vaccine expressing simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) proteins, which is administered by electroporation (EP). This FDA IND supports a biologic and device combination product.

HIV uses our immune system to infect healthy immunogenic cells and increase the opportunity of these cells to spread. HIV-1 proteins (gp120, Tat - the transactivator of transcription, Vpr, and Nef) are released from infected cells throughout the course of infection and create an ongoing HIV disease burden in a number of tissues, including the central nervous system (CNS), resulting in toxicity and damage, regardless of ART.

A substantial number of individuals with HIV disease suffer brain impairment such as HIV-1 associated cognitive impairment (HAND) and dementia. Many standard anti-retroviral drugs cannot cross the blood-brain barrier (BBB) and therefore they have no effect on HIV infection in the brain.



Source: Company Press Release